NCT02428192View on ClinicalTrials.gov

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 19, 2015

Primary Completion Date

September 20, 2018

Study Completion Date

January 28, 2021

Conditions
Metastatic LeiomyosarcomaUnresectable LeiomyosarcomaUterine Corpus Leiomyosarcoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02428192 - Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | Biotech Hunter | Biotech Hunter